Background: Chemotherapies of solid tumors commonly include 5-fluorouracil (5-FU). With standard doses of 5-FU, substantial inter-patient variability has been observed in exposure levels and treatment response. Recently, improved outcomes in colorectal cancer patients due to pharmacokinetically guided 5-FU dosing were reported. We aimed at establishing a rapid and sensitive method for monitoring 5-FU plasma levels in cancer patients in our routine clinical practice. Methods: Performance of the Saladax My5-FU ™ immunoassay was evaluated on the Roche Cobas ® Integra 800 analyzer. Subsequently, 5-FU concentrations of 247 clinical plasma samples obtained with this assay were compared to the results obtained by liquid chromatography-tandem mass spectrometry (LC-MS/MS) and other commonly used clinical analyzers (Olympus AU400, Roche Cobas c6000, and Thermo Fisher CDx90). Results: The My-FU assay was successfully validated on the Cobas Integra 800 analyzer in terms of linearity, precision, accuracy, recovery, interference, sample carryover, and dilution integrity. Method comparison between the Cobas Integra 800 and LC-MS/MS revealed a proportional bias of 7% towards higher values measured with the My5-FU assay. However, when the Cobas Integra 800 was compared to three other clinical analyzers in addition to LC-MS/MS including 50 samples representing the typical clinical range of 5-FU plasma concentrations, only a small proportional bias ( ≤ 1.6%) and a constant bias below the limit of detection was observed.
Introduction
The anticancer drug 5-fluorouracil (5-FU) is commonly used in combination chemotherapies of solid tumors [ 1 ] . In general, 5-FU is administered by continuous intravenous infusion, bolus injection or as an oral prodrug formulation (e.g., capecitabine). Substantial inter-individual variability in drug exposure and therapy response has been observed in the Caucasian population at standard 5-FU doses [ 2 , 3 ] . Approximately 10% -20% of patients treated with 5-FU-based regimens develop severe toxicities of grade 3 or higher as assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE). It has been observed that the majority of patients exhibit drug levels outside the therapeutic range and that more than 50% of patients do not benefit from standard 5-FU therapies [ 1 ] .
In the current clinical practice, dosing of 5-FU is commonly based on the patient ' s body surface area (BSA), even though it has been shown that BSA is a poor predictor of systemic drug exposure [ 4 -6 ] . Several studies have reported a relationship between drug exposure and response in terms of both efficacy and toxicity [ 5 , 7 -9 ]. An area under the curve (AUC) of 20 -25 mg × h/L, that is calculated for 5-FU as plasma concentration (mg/L) at steady state multiplied by infusion time (h), has been established as the target exposure range for optimal treatment outcome in colorectal cancer [ 10 ] . By adjusting the 5-FU dosing based on pharmacokinetic monitoring in patients receiving 5-FU monotherapy, significantly improved response rate and fewer gastrointestinal toxicities were observed compared to patients treated with conventional dosing of 5-FU [ 10 ] . These findings were recently replicated in a cohort of 157 metastatic colorectal cancer patients receiving either pharmacokinetically guided or conventional 5-FU dosing in FOLFOX (leucovorin, fluorouracil, oxaliplatin) therapy [ 11 ] . Therapeutic drug monitoring (TDM) of 5-FU during infusion therapy may be an effective tool to reduce the occurrence of adverse side effects due to drug concentration levels above the optimal range, as well as to identify under-dosed patients receiving less effective treatment. Therefore, 5-FU TDM could improve both safety and efficacy of the treatment.
Routine testing of drug levels requires an analytical method, which is accurate, rapid, and easy to use. Over the last 40 years, a variety of methods for 5-FU analysis have been developed, with recent reports applying liquid chromatography-tandem mass spectrometry (LC-MS/MS) [ 12 -18 ] . Although, LC-MS/MS methods are very sensitive and robust, the instrumentation is not yet in standard use in routine clinical laboratories. In addition, there is no certified commercial kit assay currently available for measuring 5-FU plasma levels by LC-MS/MS that can be readily used by routine laboratories. However, a nanoparticle immunoassay for 5-FU analysis (My5-FU ™ ; Saladax Biomedical, Inc., PA, USA) was recently developed and evaluated on the Olympus AU400 analyzer (Beckman Coulter, Nyon, Switzerland) [ 19 , 20 ] . In this study, we evaluated the My5-FU assay performance on the Cobas ® Integra 800 analyzer (Roche Diagnostics, Rotkreuz, Switzerland) and compared results from clinical plasma samples to those obtained by LC-MS/MS and by three other clinical analyzers. Our aim was to establish a rapid and sensitive method for monitoring 5-FU plasma levels in cancer patients in our routine clinical practice.
Materials and methods

Samples
Clinical samples were collected from 32 gastrointestinal cancer patients receiving prolonged (48 h) 5-FU infusion therapy at the Cantonal Hospital of St. Gallen, Switzerland, according to a study protocol approved by the local Ethics Committee (EKSG 08/088). All study participants provided written informed consent. A total of 197 samples were taken at several time points during the fi rst two cycles of chemotherapy. Blood samples were collected in heparinized tubes and immediately placed on ice to inhibit dihydropyrimidine dehydrogenase (DPD) enzyme activity to avoid 5-FU degradation [ 21 ] . Plasma was separated within 1 h aft er blood collection and samples were stored at − 20 ° C until analysis. Plasma samples from healthy volunteers were obtained using the same procedure as described above, and if needed, pooled and spiked to assess diff erent validation parameters. In addition, a set of 50 samples (banked samples from patients on 5-FU-containing regimens) was provided by Saladax Biomedical for method comparison.
My5-FU assay
The My5-FU immunoassay was developed for rapid determination of 5-FU levels in human plasma [ 19 ] . The assay is based on aggregation of nanoparticles that is inversely proportional to the amount of 5-FU in the sample, and it can be applied to automated clinical chemistry analyzers with photometric detection. The assay reagents, calibrators, and quality control (QC) samples for the study were provided by Saladax Biomedical. The calibrator set contained standards at 0, 150, 300, 600, 1200, and 1800 ng/mL of 5-FU, and the three QC samples (low, medium, and high control) contained 5-FU at concentrations of 225 ng/mL, 450 ng/mL, and 900 ng/mL, respectively.
Assay validation on Cobas Integra 800
The performance of the My5-FU assay was evaluated on the Cobas Integra 800 analyzer. The following validation parameters were assessed: linearity, within-run precision, within-run accuracy, total precision, between-day precision, between-day accuracy, recovery, interference, sample carryover, and dilution integrity. Prior to each run, a calibration and duplicate QC analyses were performed. QC samples had to be within the specifi cations recommended by the manufacturer: ± 8% for the low QC sample (range 207 -243 ng/mL), ± 6% for the medium QC sample (range 423 -477 ng/mL), and ± 5% for the high QC sample (range 855 -945 ng/mL).
Linearity was assessed using fi ve replicates of 11 diff erent 5-FU concentrations covering the calibration range. Samples for linearity assessment were obtained by diluting plasma spiked at a high concentration of 5-FU (1750 ng/mL) with plasma spiked at a low concentration (100 ng/mL) as described in the Clinical Laboratory Standards Institute (CLSI) Guideline EP6-A [ 22 ] . Linearity was considered acceptable if the imprecision (coeffi cient of variation, CV) at each concentration level was ≤ 15% and the inaccuracy (percent bias, %bias) was within ± 10% for concentrations ≥ 150 ng/mL and within ± 15% for concentrations < 150 ng/mL.
Within-run imprecision (CV) was determined on two separate days by analyzing on each day 20 replicates of the low and the medium QC samples and two plasma pools (pooled from fi ve healthy donors), which were spiked with 5-FU at concentrations of 240 and 700 ng/mL. Imprecision of ≤ 10% was considered acceptable following the manufacturer ' s recommendation. No specifi cations for within-run inaccuracies were stated by the manufacturer. However, according to internationally accepted guidelines for bioanalytical method validation [ 23 , 24 ] , within-run inaccuracies (%bias) should not exceed 15%. The total imprecision (CV) was determined by analyzing 40 replicates of each QC sample in fi ve days (two replicates/ sample; two samples/run; two runs/day) with a CV specifi cation limit of ≤ 15% stated by the manufacturer. Additionally, a betweenday imprecision (CV) over 31 days was evaluated by analyzing one replicate of each QC sample per day. If results of the QC replicates were outside the specifi cation range, the samples were re-analyzed and both replicates included in the between-day imprecision calculation. All three QC concentration levels over these 31 days had to be re-analyzed 14 times, thus, the between-day imprecision is reported with a total of 45 replicates per QC sample. Between-day CV of ≤ 15% was considered acceptable following the manufacturer ' s recommendation. Similarly, a between-day inaccuracy (%bias) was evaluated applying a specifi cation limit of ± 15% [ 23 , 24 ] .
Percentage recovery was assessed in 5-FU-free lithium-heparin plasma spiked at the following 5-FU concentrations: 250, 500, 1000, 1250, and 1600 ng/mL. Five replicates per sample were analyzed.
The percentage interference for compounds potentially present in plasma, i.e., lipids, bilirubin, protein, and rheumatoid factor, was assessed using the following procedure: Samples for intra-lipid (mean concentration of 1864 mg/dL), protein ( human immunoglobulin G; 12.5 g/dL), and rheumatoid factor (500 units/dL) testing were prepared by adding the respective interferent or an appropriate control (i.e., saline or plasma) to a pooled plasma sample, which was spiked with 1200 ng/mL 5-FU, following the CLSI Guideline EP7-A2 [ 25 ] . Accordingly, fi ve anonymous routine samples with a mean bilirubin concentration of 100 μ mol/L were spiked with 1000 ng/mL 5-FU to assess the relative recovery of 5-FU compared to a control sample in presence of bilirubin. For interference, a specifi cation limit of ± 10% was defi ned by the manufacturer.
Sample carryover was assessed in one run with randomly distributed replicates of two calibrator samples with low (n = 11) or high (n = 10) 5-FU concentration, 150 or 1800 ng/mL, respectively. Finally, the dilution integrity of plasma samples was evaluated up to 10-fold using water, zero calibrator standard, and 0.9% sodium chloride solution (B. Braun, Melsungen, Germany).
Method comparison
For method comparison, 247 human plasma samples were analyzed with the My5-FU immunoassay and an LC-MS/MS assay. Of these, a set of 50 samples was provided by Saladax Biomedical, whereas the rest of the samples were from cancer patients treated with 5-FUbased regimens at the Cantonal Hospital of St. Gallen. Samples containing 5-FU concentrations above the linear calibration range of the My5-FU assay were diluted up to 10-fold with water before analysis. Most of the LC-MS/MS analyses were performed as described earlier on a QTRAP ® 4000 linear ion trap quadrupole mass spectrometer (AB SCIEX, Darmstadt, Germany) [ 12 ] . A subset of samples was analyzed applying the same method with fi ne adjustments to a newer version of this LC-MS/MS system, i.e., a QTRAP 5500 (AB SCIEX). The specifi c MS/MS parameters can be requested from the authors. The results obtained on Cobas Integra 800 analyzer and LC-MS/MS for the subset of 50 samples were also compared to results obtained using the My5-FU assay on three other automated clinical analyzers, namely Olympus AU400, Roche Cobas c6000, and Thermo Fisher CDx90 (data provided by Saladax Biomedical).
For each method comparison (method 1 vs. method 2), results were compared using the Passing-Bablok regression analysis generating a linear equation with calculated values for intercept and slope [ 26 ] . The intercept value represents a measure for potential systematic diff erences between methods. If the 95% confi dence interval (CI) of the intercept contains zero, methods show no evidence for a systematic diff erence. However, if the 95% CI does not include zero, a constant bias between the methods is present. Accordingly, if the 95% CI of the slope does not include one, a proportional bias between the methods is detected.
To test the validity of the linear model, the Passing-Bablok analysis includes a cumulative sum (Cusum) linearity test [ 26 ] . The threshold for rejecting the null hypothesis of a linear relationship was set to α = 10%. Correlation analysis was additionally performed for all method comparisons obtaining a squared Pearson correlation coeffi cient ( )
.
Pearson R The degree of agreement between methods was further evaluated by using the Bland-Altman analysis, plotting the mean percent diff erence against the average of both methods [ 27 ] .
The method comparison analyses were performed with the Analyse-it ® v2.20 soft ware add in for Microsoft ® Excel ™ (Microsoft Corporation, Redmond, WA, USA).
Results
Assay validation on Cobas Integra 800
The assay was found to be linear over the entire concentration range of 5-FU (100 -1750 ng/mL). Linearity was described with the following linear regression equation: y = 1.09 × x -25.9. The CV of all concentration levels was ≤ 3.7%, and the %bias was ≤ 7.4%.
The defined specification criteria were met for imprecision and inaccuracy. Within-run imprecision was tested by analyzing 20 replicates of the low and the medium QC sample and two pooled plasma samples spiked with 5-FU on two separate days. For QC samples, the withinrun CV ranged from 0.95% to 3.9% and for pooled plasma samples from 0.65% to 2.2% ( Table 1 ) , being within the acceptable specification limit ( ≤ 10%). The within-run %bias for QC samples ranged from 4.8% to 7.4% and for pooled samples from 2.2% to 8.6%, being also within the specification criteria ( ± 15%). Total CV (n = 40) for the low, the medium, and the high QC concentration levels were 3.5%, 2.7%, and 1.4% (specification limit: ≤ 15%), respectively. Similarly, between-day CVs (n = 45) of 5.6%, 3.5%, and 2.1% (specification limit: ≤ 15%) and %biases of 3.7%, 3.8%, and 2.4% (specification limit: ± 15%) were obtained for the respective QC samples.
The percentage recovery for different 5-FU concentrations ranged from 99% to 105% ( Table 2 ) , and was thus within the acceptable range (96% -108%) given by the manufacturer.
Low interference by bilirubin ( − 5%), total protein (4%), and rheumatoid factor ( − 2%) was observed. However, intra-lipids showed an interference of 11%.
Sample carryover was evaluated using randomly distributed replicates (n = 21) of low and high 5-FU calibrator samples (150 and 1800 ng/mL, respectively). Since a CV of 2.6% and %bias of 7.4% was observed for the low concentration sample, the preceding high concentration sample had no influence on the low sample indicating the absence of any carryover effects.
Finally, a 10-fold dilution of three clinical plasma samples with water, zero calibrator standard or 0.9% sodium chloride solution yielded an imprecision of ≤ 10%.
Method comparison
Of the 247 clinical samples analyzed for the method comparison, 107 (43%) contained 5-FU concentrations above Figure 1 . A linear equation of Cobas Integra 800 (ng/mL) = 1.08 × LC-MS/ MS (ng/mL) -3.96 (95% CI slope 1.06 -1.09; 95% CI intercept -14.5 -11.4) was obtained ( Table 3 ). The CI of the slope indicated a proportional bias of 8% higher values for the Cobas Integra 800 as compared to the LC-MS/ MS method. Accordingly, the Bland-Altman method revealed a similar proportional bias of 7% between the two methods ( Figure 2 ) .
Method comparison estimates between the other clinical analyzers and the Cobas Integra 800 are listed in Table 3 . The performance of the My5-FU assay was comparable between the different instruments all showing a 2 Pearson R of ≥ 0.993. They all, however, revealed a similar proportional bias with slightly higher values being obtained with the Cobas Integra 800 analyzer. In addition, a constant bias below the limit of detection ( < 52 ng/mL) was observed between Cobas Integra 800 and all other clinical analyzers.
Discussion
The My5-FU assay was successfully established on the Cobas Integra 800 analyzer and results from the analysis of 247 clinical samples showed good correlation with LC-MS/MS. Compared to the previously published validation data on Olympus AU400 analyzer [ 20 ] , we report very similar imprecision characteristics: within-run CV of 3.9% vs. 2%, and a total CV of 3.5% vs. 3.9%. Overall, the assay validation criteria were met for linearity, precision, accuracy, recovery, sample carryover, and dilution integrity.
However, an interference of 11% was observed for intralipids. This could be explained by a freezing effect, since the interference was gradually increasing while the sample was re-frozen and thawed between the analyses. Although the assay has been validated for three freezethaw cycles, it is recommended to keep plasma samples at 4 ° C until analysis, and freeze sample aliquots for longer storage. Furthermore, the preanalytical handling of the samples may have a great influence on the quality of the results. Most importantly, the residual DPD enzyme activity in the sample needs to be inhibited immediately after blood drawing as it will lead to artificially lowered 5-FU plasma concentrations, and thus, to the risk of missing patients at high risk of toxicity due to elevated steady-state 5-FU levels. The inhibition of the residual enzyme activity may be achieved by immediate cooling of the sample on ice before plasma separation, or by adding a commercially available stabilizer (provided by Saladax Biomedical) to the sample.
The Passing-Bablok and Bland-Altman analyses revealed a proportional bias towards higher values using the My5-FU assay on the Cobas Integra 800 analyzer compared to LC-MS/MS. Accordingly, slightly higher concentrations of 5-FU compared to the nominal concentrations were generally observed for QC and spiked plasma samples using the My5-FU assay ( Table 1 ) . However, the precision and the accuracy were within the acceptable range and a positive bias of 7% would not lead to an unintentional under-dosing of a patient who is on the optimal AUC target level (22.5 mg × h/L ± 11.1%). The apparent lack of such a proportional bias in the comparisons between the My5-FU assay on other clinical chemistry analyzers and the LC-MS/MS assay may be largely explained by the more than 10-fold extended range of concentration values and the five-fold larger sample size that were included in the comparison of the Cobas Integra 800 and LC-MS/MS (93 -18590 ng/mL vs. 93 -1581 ng/mL; Table 3 ). Indeed, the proportional bias in the comparison of the Cobas Integra 800 analyzer and LC-MS/MS is strongly reduced to 1.4% if the same smaller set of samples is compared ( Table 3 ) .
Since the standard infusional regimens, such as FOLFOX, use an infusion time of 48 h, the optimal steadystate levels are low (i.e., 417 -521 ng/mL with the target AUC of 20 -25 mg × h/L). Thus, the data included in the additional method comparison series based on a subset of samples (n = 50) analyzed by using the Cobas Integra 800 and three other clinical chemistry analyzers in addition to LC-MS/MS, were within a clinical range of plasma concentrations. Our results suggest that the performance of the My5-FU assay on the different analyzers is highly comparable ( Table 3 ) . Compared to the LC-MS/MS assay, only a small proportional bias and a constant bias below the limit of detection ( < 52 ng/mL) were observed.
In conclusion, we have demonstrated that the evaluated method is reliable for routine monitoring of 5-FU plasma levels in cancer patients. We confirmed the assay robustness on different analyzers commonly used in clinical laboratories. Steady-state plasma concentration levels of 5-FU are rapidly provided for physicians and the patient ' s treatment can be adjusted if necessary. This is possible because standard 5-FU therapy regimen cycles are biweekly, and delayed toxicity symptoms may occur up to several days or weeks after the first cycle of therapy. Monitoring 5-FU plasma levels may provide an effective approach to improve efficacy and safety of commonly used 5-FU-based therapies in cancer patients.
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